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Purpose: To clarify the mutation spectrum and frequency of ABCA4 in a Chinese cohort 
with Stargardt disease (STGD1).
Methods: A total of 153 subjects, comprising 25 families (25 probands and their family 
members) and 71 sporadic cases, were recruited for the analysis of ABCA4 variants. All 
probands with STGD1 underwent a comprehensive ophthalmologic examination. Overall, 
792 genes involved in common inherited eye diseases were screened for variants by 
panel-based next-generation sequencing (NGS). Variants were ﬁltered and analyzed to 
evaluate possible pathogenicity.
Results: The total variant detection rate of at least one ABCA4 mutant allele was 84.3% 
(129/153): two or three disease-associated variants in 86 subjects (56.2%), one mutant 
allele in 43 subjects (28.1%), and no variants in 24 subjects (15.7%). Ninety-six variants 
were identiﬁed in the total cohort, which included 62 missense (64%), 15 splicing (16%), 
11 frameshift (12%), 6 nonsense (6%), and 2 small insertion or deletion (2%) variants. 
Thirty-seven novel variants were found, including a de novo variant, c.4561delA. The 
most prevalent variant was c.101_106delCTTTAT (10.5%), followed by c.2894A > G 
(6.5%) and c.6563T > C (4.6%), in STGD1 patients from eastern China.
Conclusion: Thirty-seven novel variants were detected using panel-based NGS, including 
one de novo variant, further extending the mutation spectrum of ABCA4. The common 
variants in a population from eastern China with STGD1 were also identiﬁed.
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INTRODUCTION
Stargardt disease (STGD1, OMIM 248200), also known as juvenile 
macular degeneration, is a hereditary macular dystrophy 
characterized by bilateral or sequential central visual loss in 
early adolescence (North et al., 2014; Tanna et al., 2017). STGD1 
is one of the most common causes of macular dystrophy in 
childhood, accounting for about 7% of all retinal dystrophy, 
with an incidence of 1:10,000 (Blacharski, 1988). The fundus of 
STGD1 patients commonly presents with yellow-white flecks, 
bull’s eye maculopathy, a beaten bronze appearance of the 
macula, and atrophy of retinal pigment epithelium (RPE). It is 
caused by the massive deposition of lipofuscin in RPE, followed 
by photoreceptor cell death and eventually loss of vision (Aaberg 
and Han, 1987; Anderson et al., 1995; Fishman et al., 1999; Lewis 
et al., 1999). STGD1 is an autosomal recessive disorder caused 
by variants in the ATP-binding cassette subfamily A member 4 
(ABCA4) (Allikmets, 1997).
ABCA4 (OMIM 601691), located on chromosome 1p22.1, 
is composed of 50 exons and specifically expressed in retina 
photoreceptors (Nasonkin et al., 1998). The transmembrane 
protein encoded by ABCA4 is a member of the superfamily 
of ATP-binding cassette transporters and is mainly involved 
in the transport of N-retinylidene-phosphatidylethanolamine 
(NRPE), an intermediate metabolite of vitamin A, from the disc 
membrane of the photoreceptor outer segment to the cytoplasm 
(Molday and Zhang, 2010; Quazi et al., 2012; Quazi and Molday, 
2014). Therefore, ABCA4 promotes the removal of toxic retinal 
phospholipid compounds from photoreceptor cells, and its 
dysfunction results in the degeneration of photoreceptor cells 
(Molday, 2007; Molday et al., 2009). Variants in the ABCA4 
gene are responsible for STGD1 (Allikmets, 1997), retinitis 
pigmentosa (RP) (Cremers et al., 1998; Rozet et al., 1999), cone–
rod dystrophy (CRD) (Cremers et al., 1998; Maugeri et al., 2000), 
and retinal dystrophy (Singh et al., 2006). It has been reported that 
ABCA4 is the only gene confirmed to be associated with STGD1 
(Allikmets, 1997). To date, approximately 1200 disease-related 
variants have been identified in retinopathy caused by ABCA4 
(Cornelis et al., 2017) (Human Gene Mutation Database, HGMD, 
http://www.lovd.nl/ABCA4). Among them, nearly 900 variants 
are associated with STGD1, and the majority of variant types 
are missense. The variant detection rate of at least one ABCA4 
mutant allele ranges from 70% to 90% in different STGD1 cohorts 
(Fujinami et al., 2013; Riveiro-Alvarez et al., 2013; Zernant et al., 
2014b; Jiang et al., 2016; Smaragda et al., 2018). Although the 
disease-causing ABCA4 variants are extremely heterogeneous, 
previous studies have confirmed frequent ABCA4 variants with 
ethnic specificity, such as c.2588G > C in the Western European 
population (Maugeri et al., 1999), p.Y808* in Chinese patients 
(Jiang et al., 2016), c.5714+5G > A in a Greek cohort (Smaragda 
et al., 2018), p.N965S in Denmark (Rosenberg et al., 2007), 
p.A1773V in Mexico (Chacon-Camacho et al., 2013), p.R1129L 
in Spain (Riveiro-Alvarez et al., 2013), and p.R2107H in African 
American patients (Zernant et al., 2014a).
In this study, we investigated the spectrum of ABCA4 
variants using panel-based next-generation sequencing (NGS) 
technology in a Chinese cohort with STGD1. The purpose of 
this study is to extend the mutation spectrum of ABCA4. Our 
analysis identified 37 novel disease-associated variants of ABCA4 
and determined the prevalent ABCA4 variants mainly in the 
population of eastern China. Furthermore, we identified one 
novel heterozygous variant, c.4561delA, as a de novo variant in 
the ABCA4 gene in one STGD1 patient.
MATERIALS AND METHODS
Subjects and Ethics Statement
A total of 153 subjects, comprising 25 families (25 probands and 
their relatives) and 71 sporadic cases, were recruited at the Eye 
and ENT Hospital of Fudan University from 2016 to 2018. This 
study was approved by the Ethics Committee of the Eye and ENT 
Hospital of Fudan University and in accordance with the Code of 
Ethics of the World Medical Association (Declaration of Helsinki) 
for medical research involving human subjects. All participants 
were recruited after obtaining their informed consent.
Clinical Assessment
All probands underwent a comprehensive ophthalmologic 
examination, including best corrected visual acuity (BCVA), 
slit-lamp biomicroscopy, fundus examination, fundus 
photograph, electroretinography (ERG), spectral domain optical 
coherence tomography (SD-OCT, Spectralis HRA + OCT, 
Heidelberg Engineering Inc., Heidelberg, Germany), and fundus 
autofluorescence (FAF, Spectralis HRA + OCT, Heidelberg, 
Germany). Moreover, other associated information was collected, 
including family history, age of onset, duration of disease, and 
subjective degree of vision loss. The clinical diagnosis of STGD1 
was assessed by professional ophthalmologists.
DNA Sample Collection
Genomic DNA was extracted from the peripheral blood of 
all subjects using the FlexiGene DNA Kit (Qiagen, Venlo, 
Netherlands), in accordance with the manufacturer’s protocol. 
DNA integrity was observed by 1% agarose gel electrophoresis. 
DNA samples were stored at −20°C before sequencing analysis.
Targeted Exome Sequencing and Genetic 
Analyses
Panel-based NGS was performed on all subjects in this study. We 
designed the Target_Eye_792_V2 chip with exon-capture and 
untranslated regions (UTRs) of 792 genes involved in common 
inherited eye diseases (Supplementary Table S1), in collaboration 
with BGI-Shenzhen (Shenzhen, Guangdong, China). Genomic 
DNA was sheared into fragments, and fragments containing 
the coding exons, flanking intronic regions, and promoter 
regions were captured using the Agilent SureSelect Target 
Enrichment Kit (Agilent Technologies, Inc., USA). The enriched 
libraries were sequenced on a MGISEQ-2000 platform (BGI, 
Inc., Shenzhen, China) in accordance with the manufacturer’s 
protocols. Sequencing reads were mapped to the reference 
human genome (hg38) using a Burrows–Wheeler Aligner (BWA, 
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http://bio-bwa.sourceforge.net/). All identified variants were 
annotated using the following four databases: 1,000 Genomes 
Project (http://browser.1000genomes.org/), dbSNP (http://
www.ncbi.nlm.nih.gov/projects/SNP/), ESP6500 (http://evs.
gs.washington.edu/EVS/), and ExAC (http://exac.broadinstitute.
org). The variants with minor allele frequency (MAF) < 0.1% 
were selected to find possible deleterious variants. In addition, 
potential pathogenic variants were predicted using the following 
three online tools: Sorting Intolerant from Tolerant (SIFT, http://
sift.jcvi.org/), Polymorphism Phenotyping v2 (PolyPhen-2, 
http://genetics.bwh.harvard.edu/pph2/), and MutationTaster 
software (http://www.mutationtaster.org/). Then, the remaining 
variants were prioritized using ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/), HGMD (http://www.hgmd.cf.ac.uk/ac/index.
php), and Online Mendelian Inheritance in Man (OMIM, http://
www.omim.org/) in combination with their potential deleterious 
impacts, genotype–phenotype relationships, and variant reports. 
In accordance with the American College of Medical Genetics 
(ACMG) and genomics guidelines, variants were classified as 
pathogenic, likely pathogenic, uncertain significance, likely 




A total of 153 subjects were presented in this study, including 
25 families (25 probands and their relatives, 82 subjects in 
total) and 71 sporadic cases. The average age of the total cohort 
was 33 years (range 5–76 years), of which the majority were 
under 40 years old, about 63% (95 subjects) (Figure 1A). As 
shown in Figure 1B, 87% of the subjects were from eastern 
China, while the others were from regions including south 
China and central China. The clinical characteristics of 101 
patients with a clinically definitive diagnosis are presented in 
Table 1. The average age of the patients was 28.0 years (range 
6–76 years) and the average age of onset was 19.0 years (range 
2–70 years). The average duration of disease in the 101 patients 
was 10 years. In addition, the average BCVA of the right eye 
and left eye were 0.50 (range 0.1–1.0) and 0.50 (range 0.1–1.2), 
respectively. Fundus examination in STGD1 patients revealed 
macular atrophy and the degeneration of photoreceptors and 
RPE cells.
Variant Detection Rates of ABCA4
Of the 153 subjects screened by panel-based NGS, ABCA4 
mutant variants were identified in 129 cases, resulting in a total 
variant detection rate of 84.3%: two or three ABCA4 disease-
associated variants in 86/153 (56.2%) subjects, one disease-
causing allele in 43/153 (28.1%) subjects, and no variants in 24 
subjects (15.7%) (Table 2). Furthermore, the variant detection 
rates in the families and sporadic cases were 87.8% and 80.3%, 
respectively (Table 2). Among 25 probands in 25 families, three 
ABCA4 mutant variants were identified in only one patient, two 
disease-associated variants were identified in 28 patients, and no 
variants in one proband. In sporadic cases, potential pathogenic 
TABLE 1 | Clinical characteristics in 101 patients with STGD1.
Average age (years) 28.0 (6–76)
Average age of onset (years) 19.0 (2–70)
Average duration of disease (years) 10.0 (1–50)
Average BCVA (right eye) 0.5 (0.1–1.0)
Average BCVA (left eye) 0.5 (0.1–1.2)
FIGURE 1 | Basic information on the 153 subjects in this study. (A) The age distribution of the total cohort. (B) The geographical distribution of the population.
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variants of ABCA4 were identified in 57 of the 71 patients (80.3%). 
Consistent with previous studies, the majority of patients with 
STGD1 carried compound heterozygous variants.
Genetic Analyses
Ninety-six distinct variants of ABCA4 were identified in the total 
cohort, including 37 novel variants and 59 known variants. The 
detailed genetic analyses of 96 ABCA4 variants are summarized 
in Supplementary Table S2 and Supplementary Table S3. 
All variants and cases with variants are uploaded at http://
www.lovd.nl/ABCA4. As shown in Figure 2, 96 variants were 
widely distributed in 50 exons of ABCA4. Analysis revealed six 
different mutant variants each in exons 3 and 13; four different 
variants each in exons 8, 22, 23, and 35; and one to three in 
each of the remaining 29 exons. In the six functional domains 
of the ABCA4 protein, mutant variants were mainly distributed 
in transmembrane domain 1 (TMD1) and nucleotide-binding 
domains 1 and 2 (NBD1 and NBD2). Moreover, there were 15 
variants observed in the introns of ABCA4, including introns 7, 8, 
10, 12, 13, 23, 26, 28, 29, 36, 38–40, 44, and 45. Through analysis 
with Human Splicing Finder (http://www.umd.be/HSF3/), these 
intronic mutations mainly affected splice donor or acceptor sites 
(Supplementary Table S2).
The 96 mutant variants identified in the total cohort included 
missense (62/96, 64%), nonsense (6/96, 6%), splicing (15/96, 16%), 
frameshift (11/96, 12%), and small insertion or deletion (2/96, 2%) 
variants. Overall, there were 38 pathogenic variants (39.5%), 26 
likely pathogenic variants (27.1%), and 32 uncertain-significance 
variants (33.4%). The majority of uncertain-significance variants 
were novel variants. The 64 pathogenic/likely pathogenic variants 
included missense (34/64, 53%), splicing (12/64, 19%), frameshift 
(11/64, 17%), nonsense (6/64, 9%), and small deletion (1/64, 2%) 
variants (Figure 3A). As shown in Table 3, there were 10 prevalent 
variants in the total cohort. All of these were pathogenic variants, 
mainly missense variants. The three most prevalent variants were 
c.101_106delCTTTAT p.Ser34_Leu35del (with an allele frequency 
of 10.5%), c.2894A > G p.Asn965Ser (6.5%), and c.6563T > C 
p.Phe2188Ser (4.6%). In addition, the most prevalent variant 
c.101_106delCTTTAT was found in 16 subjects (15 heterozygous, 1 
homozygous). The second most prevalent variant c.2894A > G was 
found in 10 subjects (all heterozygous). The third most prevalent 
variant c.6563T > C was detected in 7 subjects (all heterozygous).
Novel Variants of the ABCA4 Gene
Thirty-seven novel variants were identified in this study 
(Supplementary Table S2), including missense (15/37, 40%), 
frameshift (8/37, 22%), splicing (7/37, 19%), nonsense (6/37, 
16%), and small insertion (1/37, 3%) variants (Figure 3B). These 
novel variants were found in 61 subjects, of whom 56 were in a 
heterozygous state and 5 homozygous. Of the 37 novel variants, 
there were 18 pathogenic/likely pathogenic variants (48.6%) 
and 19 uncertain-significance variants (51.4%). The 18 novel 
pathogenic/likely pathogenic variants included frameshift (8/18, 
45%), nonsense (6/18, 33%), and splicing (4/18, 22%) variants. 
The uncertain-significance variants mainly included missense 
variants. Among the 37 novel variants, the most prevalent variant 









3 1/1.2 2/2.8 3/2.0
2 28/34.2 55/77.5 83/54.2
1 43/52.4 0/0 43/28.1
0 10/12.2 14/19.7 24/15.7
82/100 71/100 153/100
FIGURE 2 | Distribution and frequency of the ABCA4 mutant variants identiﬁed in this study.
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was a frameshift variant c.1006delT with an allele frequency of 
3.3% (Table 3), which was found in 5 subjects (all heterozygous). 
Variants c.3055A > G, c.2894A > G, and c.1372C > T were detected 
in compound heterozygosity with variant c.1006delT. In addition, 
four variants were detected three times in the cohort, namely, 
c.6625C > T, c.3634G > T, c.1382_1383delAA, and c.1372C > T. 
Two frameshift variants c.1006delT and c.1382_1383delAA and 
a nonsense variant c.6625C > T were identified as pathogenic 
variants. Furthermore, one novel heterozygous variant c.4561delA 
was considered as a de novo variant in one patient with STGD1, 
which was not found in either of the parents. Variant c.4561delA 
was detected in compound heterozygosity with variant c.95C > T.
DISCUSSION
In the present study, 96 disease-associated ABCA4 variants were 
identified in the STGD1 cohort by panel-based NGS technology. 
Among them, 37 novel variants were detected.
In 153 subjects, the overall variant detection rate for ABCA4 
was 84.3% (129/153), which was not significantly different from 
the mutation detection rate (70%–90%) in previous studies 
(Fujinami et al., 2013; Riveiro-Alvarez et al., 2013; Zernant 
et al., 2014b; Jiang et al., 2016; Smaragda et al., 2018). In recent 
studies, the variant detection rate for ABCA4 in STGD1 patients 
from European and American countries is basically around 80%, 
while the variant detection rate in the Chinese population can 
reach more than 90%. In this study, 15 probands were negative 
after genetic analysis of 792 genes associated with inherited eye 
diseases. On the one hand, these probands may have large deletion 
or duplication variants; on the other hand, new pathogenic genes 
responsible for STGD1 may exist. Therefore, analysis of copy 
number variants, array CGH, and WGS will be performed on 
these patients in order to find such variants and important new 
genes. In addition, similar to previous studies, the vast majority 
of patients with STGD1 were compound heterozygotes, and 
only 9 patients were identified as homozygotes. Supplementary 
Table S4 lists homozygous variants in STGD1 cases with their 
FIGURE 3 | Genetic analyses of the mutant variants identiﬁed in the total cohort. (A) Sixty-four pathogenic/likely pathogenic variants were identiﬁed in this study, 
including missense (n = 34), splicing (n = 12), frameshift (n = 11), nonsense (n = 6), and small deletion (n = 1) variants. (B) Thirty-seven novel variants were identiﬁed, 
including missense (n = 15), frameshift (n = 8), splicing (n = 7), nonsense (n = 6), and small insertion (n = 1) variants.
TABLE 3 | Ten prevalent variants of ABCA4 gene in 153 subjects.
Gene Nucleotide change Amino acid
change
Clinical significance1 Allele frequency
ABCA4 c.101_106 delCTTTAT p.(Ser34_Leu35del) Pathogenic 10.5%
ABCA4 c.2894A>G p.(Asn965Ser) Pathogenic 6.5%
ABCA4 c.6563T>C p.(Phe2188Ser) Pathogenic 4.6%
ABCA4 c.1819G>A p.(Gly607Arg) Pathogenic 3.3%
ABCA4 c.1006delT2 p.(Ser336Profs*38) Pathogenic 3.3%
ABCA4 c.5761G>A p.(Val1921Met) Pathogenic 2.6%
ABCA4 c.1804C>T p.(Arg602Trp) Pathogenic 2.6%
ABCA4 c.6282+1G>A p.? Pathogenic 2.6%
ABCA4 c.6389T>A p.(Met2130Lys) Pathogenic 2.6%
ABCA4 c.1561delG p.(Val521Serfs*47) Pathogenic 2.6%
1ABCA4 variants were classified as pathogenic according to the American College of Medical Genetics (ACMG) and genomics guidelines for the more recent cases.
2Variant c.1006delT was a novel variant detected in this study.
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respective ages at onset. In this way, the severity of missense 
variants can be deduced.
Consistent with previous studies (Hargitai et al., 2005; Jiang et al., 
2016), 96 ABCA4 variants identified in this study were distributed 
throughout the coding region of ABCA4. Besides, the variants were 
all mainly distributed in the TMD1, NBD1, and NBD2 domains 
of the ABCA4 protein. This suggests that the three functional 
domains may be high-risk regions in the Chinese cohort, although 
previous studies of other ethnicities show no variant hot spots in 
ABCA4 (Fumagalli et al., 2001; Fujinami et al., 2019).
In accordance with ACMG and genomics guidelines, 64 
pathogenic/likely pathogenic variants were identified in this 
study, of which missense variants accounted for 53%. Besides, 
32 uncertain-significance variants were found in 49 subjects, 
including 28 missense variants, 3 splicing variants, and one small 
insertion variant. These uncertain-significance variants did not 
cause significant protein damage, or had an uncertain impact.
In the present study, the three most prevalent variants were 
c.101_106delCTTTAT (10.5%), c.2894A > G (6.5%), and 
c.6563T > C (4.6%), which differed from the common variants 
(c.2424C > G 4.7%, c.6563T > C 3.7%, c.2894A > G 3.1%, and 
c.101_106delCTTTAT 3.1%) previously reported in a Chinese 
cohort (Jiang et al., 2016). Moreover, the frequency of common 
variants in this study was significantly higher than that previously 
reported in Chinese patients. The most prevalent variant 
c.101_106delCTTTAT in our study was the third most common 
variant in the previous Chinese cohort, while the most prevalent 
variant c.2424C > G previously reported in Chinese patients was 
only detected in two patients in this study. Based on our subjects, 
mainly coming from eastern China, it is possible that these three 
prevalent variants are specific to STGD1 patients in eastern China. 
Compared with other ethnic groups, the most prevalent variant 
c.2894A > G in Danish patients (Rosenberg et al., 2007) was 
the second most common variant in our study. Many common 
mutant variants identified in other countries were all absent in 
the present study, such as p.G863A/p.G863del in the Northern 
European population (Maugeri et al., 1999), p.[L541P;A1038V] 
in Germany (Rivera et al., 2000), p.R1129L in Spain (Valverde 
et al., 2006), and p.A1773V in Mexico (Chacon-Camacho et al., 
2013). It has been reported that variant c.2894A > G can affect 
substrate transport across membranes by reducing ATPase 
activities of the ABCA4 protein (Quazi and Molday, 2013). 
Based on the analyses of MutationTaster and ABCA4 protein 
structure, variant c.101_106delCTTTAT in the transmembrane 
domain might destroy transmembrane α-helices, resulting in the 
dysfunction of ABCA4 transport. In addition, variant c.6563T > 
C in the cytoplasmic soluble-protein region responsible for ATP 
hydrolysis might affect ATPase activities.
Although more than 1,000 variants of ABCA4 have been 
reported according to HGMD, recent studies have revealed that 
there are still novel disease-related variants to be found in STGD1 
patients. In the present study, 37 novel variants were identified, 
including fifteen missense, eight frameshift, seven splicing, six 
nonsense, and one small insertion variant. The results showed 
that 37 novel variants were distributed in 19 exons and 7 introns 
of ABCA4. Among them, three different mutant variants were 
detected in exon 36, and two different variants each in exons 2, 
8, 11, 20–22, 25, and 48. Of the 37 novel variants, 18 pathogenic/
likely pathogenic variants and 19 uncertain-significance variants 
were identified according to ACMG and genomics guidelines. The 
19 uncertain-significance variants included 16 missense variants 
with no significant protein damage and 3 splicing variants with 
no significant impact on splicing. In addition, more than half of 
the novel variants were detected only once. A frameshift variant 
c.1006delT was the most prevalent variant among them, which 
was found in one sporadic case and two families (two probands 
and two family members). Notably, we identified one de novo 
frameshift variant in the ABCA4 gene that has not previously 
been reported, c.4561delA (p.Ile1521Phefs*5), in one patient. 
This patient presented with an early age of onset and severe 
clinical symptoms with extensive chorioretinal and RPE atrophy.
CONCLUSION
In conclusion, we report here the mutation spectrum of ABCA4 in 
a large Chinese cohort, with a total variant detection rate of 84.3%. 
Our analysis has identified 37 novel disease-associated variants, 
extending the mutation spectrum of ABCA4. Among these, 
one novel heterozygous variant, c.4561delA, was determined as 
a de novo variant. Moreover, the three most prevalent variants 
were identified in STGD1 patients from eastern China. Genetic 
testing of STGD1 patients will improve the accuracy of clinical 
diagnosis, and improvement of the ABCA4 mutation spectrum in 
the Chinese population will be more conducive to gene screening 
of STGD1 patients in the future.
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